Evidence map›Paper›PMID 35285979›Full record

ArticleAmerican journal of hematology2022

Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma.

Andrew M Evens, Justin S Brandt, Cody J Peer, Tyler Yin, Dale Schaar, Faheem Farooq, Brett Mozarsky, William D Figg, Elad Sharon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew M EvensDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.ORCID 0000-0002-6900-1824
Justin S BrandtDepartments of Medicine and Maternal Fetal Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
Cody J PeerClinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Tyler YinClinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Dale SchaarDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Faheem FarooqDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.ORCID 0000-0003-0857-1468
Brett MozarskyClinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
William D FiggClinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
Elad SharonCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.

Funding

Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hodgkin DiseaseFemaleHumansImmunologic FactorsImmunotherapyPregnancyImmunologic Factors

Identifiers

PMID35285979
PMCPMC9314600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.